Abstract:OBJECTIVE:To assess the neuroimaging features of Parkinson's Disease and dystonia by transcranial sonography (TCS).METHODS:63 Parkinson's Disease patients, 32 dystonia patients and 81 controls underwent TCS in blind manner. The echo of the substantia nigra (SN) was classified into I-V as half quantitative data. The echo of SN≥III was considered to be positively enhanced, the hyperechogenicity were measured and the hyper-substantia nigra/midbrain (S/M) were calculated. The echo of the lentiform nucleus (LN) was classified into I-III as half quantitative data. The echo of LN≥II was considered to be positively increased and were measured.RESULT:Semi-quantitative analysis: the ratio of the patients with SN≥III was greater in Parkinson's Disease patients (60.32%, 38/63) than in dystonia patients (12.50%, 4/32) and normal controls (11.11%, 8/72, χ2=19.67, 36.22, P<0.01, respectively), the ratio of the patients with LN≥II was greater in dystonia patients (65.62%, 21/32) than in Parkinson's Disease patients (20.63%, 13/63) and in controls (8.33%, 6/72, χ2=18.69, 37.83, P<0.01, respectively). Quantitative analysis:the median and quartile (M/Q) of the SN hyperechogenieity area in Parkinson's Disease patients [0.73 (0.53) cm2] was greater than in dystonia patients [0.56 (0.53) cm2] and in controls [0.44 (0.19) cm2, H=10.05, P=0.007], the S/M in Parkinson's Disease patients was greater [15.7% (11.5%)] than in dystonia patients [(13.8% (14.2%)] and in controls [8.9% (2.9%), H=6.96, P=0.031]. The M/Q of LN hyperechogenieity area in dystonia patients was greater [0.50 (0.33) cm2] than in Parkinson's Disease patients [0.45 (0.22) cm2] and in controls [0.35 (0.17) cm2, H=10.87, P=0.004].CONCLUSION:TCS might find the specific hyperechogenicity of SN in Parkinson's Disease patients (60.32%) and hyperechogenicity of LN in dystonia patients (65.63%), which could provide useful informations to distinguish Parkinson's Disease from dystonia.

Transcranial ultrasound examination of the brain parenchyma in neuropsychiatric diseases

Transcranial sonography in patients with Parkinson disease and Alzheimer disease

Application of transcranial ultrasonography in diagnosis of Parkinson disease

Transcranial Sonography Characteristics of Cerebellar Neurodegenerative Ataxias

Transcranial sonography in pantothenate kinase-associated neurodegeneration

Significance of transcranial sonography in diagnosis of parkinson disease

Accuracy of transcranial brain parenchyma sonography in the diagnosis of dementia with Lewy bodies

Transcranial sonography in early-onset Parkinson's disease

Transcranial sonography in diagnosis and differential diagnosis of Parkinson's disease

Neuroimaging Characteristics of Transcranial Sonography in Parkinson's Disease Patients with Depression

Transcranial sonography in patients with multiple system atrophy and Parkinson's disease

Advancements in understanding substantia nigra hyperechogenicity via transcranial sonography in Parkinson's disease and its clinical implications

The Study Transcranial Sonography on Parkinson' S Disease and Essential Tremor

Application and progress of transcranial substantial ultrasound in Parkinson's disease

Transcranial sonography in late-onset Parkinson's disease

[The Neuroimaging Features of Parkinson's Disease and Dystonia by Transcranial Sonography].

The characteristic and biomarker value of transcranial sonography in cerebellar ataxia

Transcranial Sonographic Alterations of Substantia Nigra and Third Ventricle in Parkinson's Disease with or Without Dementia.

Transcranial sonography on Parkinson’s disease and essential tremor in a Chinese population

Predictive value of transcranial sonography in the diagnosis of Parkinson disease

Transcranial brain parenchyma sonography in patients with juvenile myoclonic epilepsy